2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 min sitten · MuokattuCannot find many press mentions in the last 24 hours. Bioword has a top story which is from ASGCT 2026: Circular RNA, the new beast in gene and cell therapy https://www.bioworld.com/newsletters/25-bioworld-science Popular Stories at Bioworld is topped by this one: https://www.bioworld.com/articles/731268-asgct-2026-circular-rna-the-new-beast-in-gene-and-cell-therapy
·29 min sittenThink long-term, until now Boston or micro index has not had a big influence on the price It is only in the Nordics that the stock exchange has closed In Germany, the price is just a little over 1€
·9 min sittenI also don't see any drama in this, regardless Boston generates massive attention around both technology and the company. News can come here at any time, being on the sidelines is a risky sport.
·55 min sittenAll those who ask about tomorrow's etc. etc. it's completely irrelevant. This stock has many exciting months / years ahead of it. Whether it's +5 % tomorrow or - is irrelevant compared to the overall total later.- ·59 min sittenThe great strength in the case right now is that Circio can build momentum in several stages: first posters, then oral presentation, then a focused RNA-summit, and then BIO as a more commercial arena. Circular & Self-Amplifying RNA Summit is precisely described as a conference for the transition from emerging modality to clinical reality, with a focus on durable expression, redosing, delivery, CMC, and regulatory strategies. In short: ASGCT strengthens the scientific validation. The Summit 26.–28. May can strengthen the industrial positioning. BIO San Diego can become more relevant for concrete partner processes. Exciting! Dare to guess a price over 20 in July.
·1 t sittenOn this forum there are many contributions, speculations, viewpoints, AI productions etc, and with different intentions. Having followed the company over the last year as a shareholder, I struggle to see the really big news after the presentation last night. In my opinion, no news emerged during the review that was not previously known. It would therefore be good if some serious individuals on this forum could point to news from the presentation that is expected to have an effect on the share price, considering the period we are in with the calculation of the volume-weighted average price in the period 8 - 22 May, and which will form the basis for the issuance of new shares and hopefully increased equity for Circio.·20 min sittenThere might be talk of publicity regarding what a small company has said before.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 min sitten · MuokattuCannot find many press mentions in the last 24 hours. Bioword has a top story which is from ASGCT 2026: Circular RNA, the new beast in gene and cell therapy https://www.bioworld.com/newsletters/25-bioworld-science Popular Stories at Bioworld is topped by this one: https://www.bioworld.com/articles/731268-asgct-2026-circular-rna-the-new-beast-in-gene-and-cell-therapy
- ·29 min sittenThink long-term, until now Boston or micro index has not had a big influence on the price It is only in the Nordics that the stock exchange has closed In Germany, the price is just a little over 1€·9 min sittenI also don't see any drama in this, regardless Boston generates massive attention around both technology and the company. News can come here at any time, being on the sidelines is a risky sport.
- ·55 min sittenAll those who ask about tomorrow's etc. etc. it's completely irrelevant. This stock has many exciting months / years ahead of it. Whether it's +5 % tomorrow or - is irrelevant compared to the overall total later.
- ·59 min sittenThe great strength in the case right now is that Circio can build momentum in several stages: first posters, then oral presentation, then a focused RNA-summit, and then BIO as a more commercial arena. Circular & Self-Amplifying RNA Summit is precisely described as a conference for the transition from emerging modality to clinical reality, with a focus on durable expression, redosing, delivery, CMC, and regulatory strategies. In short: ASGCT strengthens the scientific validation. The Summit 26.–28. May can strengthen the industrial positioning. BIO San Diego can become more relevant for concrete partner processes. Exciting! Dare to guess a price over 20 in July.
- ·1 t sittenOn this forum there are many contributions, speculations, viewpoints, AI productions etc, and with different intentions. Having followed the company over the last year as a shareholder, I struggle to see the really big news after the presentation last night. In my opinion, no news emerged during the review that was not previously known. It would therefore be good if some serious individuals on this forum could point to news from the presentation that is expected to have an effect on the share price, considering the period we are in with the calculation of the volume-weighted average price in the period 8 - 22 May, and which will form the basis for the issuance of new shares and hopefully increased equity for Circio.·20 min sittenThere might be talk of publicity regarding what a small company has said before.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 min sitten · MuokattuCannot find many press mentions in the last 24 hours. Bioword has a top story which is from ASGCT 2026: Circular RNA, the new beast in gene and cell therapy https://www.bioworld.com/newsletters/25-bioworld-science Popular Stories at Bioworld is topped by this one: https://www.bioworld.com/articles/731268-asgct-2026-circular-rna-the-new-beast-in-gene-and-cell-therapy
- ·29 min sittenThink long-term, until now Boston or micro index has not had a big influence on the price It is only in the Nordics that the stock exchange has closed In Germany, the price is just a little over 1€·9 min sittenI also don't see any drama in this, regardless Boston generates massive attention around both technology and the company. News can come here at any time, being on the sidelines is a risky sport.
- ·55 min sittenAll those who ask about tomorrow's etc. etc. it's completely irrelevant. This stock has many exciting months / years ahead of it. Whether it's +5 % tomorrow or - is irrelevant compared to the overall total later.
- ·59 min sittenThe great strength in the case right now is that Circio can build momentum in several stages: first posters, then oral presentation, then a focused RNA-summit, and then BIO as a more commercial arena. Circular & Self-Amplifying RNA Summit is precisely described as a conference for the transition from emerging modality to clinical reality, with a focus on durable expression, redosing, delivery, CMC, and regulatory strategies. In short: ASGCT strengthens the scientific validation. The Summit 26.–28. May can strengthen the industrial positioning. BIO San Diego can become more relevant for concrete partner processes. Exciting! Dare to guess a price over 20 in July.
- ·1 t sittenOn this forum there are many contributions, speculations, viewpoints, AI productions etc, and with different intentions. Having followed the company over the last year as a shareholder, I struggle to see the really big news after the presentation last night. In my opinion, no news emerged during the review that was not previously known. It would therefore be good if some serious individuals on this forum could point to news from the presentation that is expected to have an effect on the share price, considering the period we are in with the calculation of the volume-weighted average price in the period 8 - 22 May, and which will form the basis for the issuance of new shares and hopefully increased equity for Circio.·20 min sittenThere might be talk of publicity regarding what a small company has said before.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt